Shares of Latigo Biotherapeutics, Inc. (NASDAQ:LTGO – Get Free Report) saw an uptick in trading volume on Tuesday. Approximately 535,285 shares were traded during trading, an increase of 86% from the average daily volume of 288,307 shares. The stock last traded at $13.60 and had previously closed at $13.35.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price objective for the company. Wall Street Zen upgraded Latigo Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Guggenheim assumed coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 target price for the company. Weiss Ratings started coverage on Latigo Biotherapeutics in a research note on Tuesday, November 3rd. They issued a “sell (e-)” rating for the company. Finally, The Goldman Sachs Group began coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $73.00 price target on the stock. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Latigo Biotherapeutics currently has an average rating of “Moderate Buy” and an average price target of $52.25.
Check Out Our Latest Report on LTGO
Latigo Biotherapeutics Stock Up 1.4%
The firm has a 50 day simple moving average of $17.39.
Latigo Biotherapeutics (NASDAQ:LTGO – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.55) earnings per share (EPS) for the quarter.
About Latigo Biotherapeutics
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid medicines for pain. Its research focuses on voltage-gated sodium channels, which play a role in transmitting pain signals. The company’s pipeline includes LTG-001, an oral, selective Nav1.8 inhibitor being developed for acute pain, along with additional investigational programs targeting pain conditions. Latigo’s work is aimed at providing alternatives to opioid-based pain treatment. Its product candidates are investigational and have not been established as safe or effective for any use.
See Also
- Five stocks we like better than Latigo Biotherapeutics
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
Receive News & Ratings for Latigo Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Latigo Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
